News

The companies are not disclosing specific terms of the settlement and license agreements, except that Cadence has granted Fresenius Kabi a non-exclusive right to market an intravenous acetaminophen

CL-108 combines 12.5 mg of immediate-release promethazine with 7.5 mg of hydrocodone and 325 mg of acetaminophen. Charleston recently completed a 465-patient phase 3 trial studying the effects

The approval in the European Union (EU) was based on results of the Phase III Aurelia trial which included women with recurrent, platinum-resistant ovarian cancer who received either

Sivextro is a short, six-day course therapy for the treatment of serious skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The drug was approved by the

Polycythemia vera is a form of blood cancer that leads to the overproduction of normal red blood cells, white blood cells and platelets. The filing of the sNDA

D360 is used by scientists in both discovery and pre-clinical research. It allows them to search, analyze and share their data without the need for constant IT support,

Kadimastem will utilize its unique platform for Merck Serono, the biopharmaceutical division of Merck, for the screening of new compounds as potential new therapeutics. Kadimastem has developed a

Under the terms of the agreement, ARIAD Pharmaceuticals (Israel) Ltd will be the Marketing Authorization Holder (MAH) of Iclusig in Israel, and Medison will be responsible for sales

Bioavailability is an important measurement of how efficiently a substance is taken into the body. Published scientific studies report CBD oral bioavailability in the range of between 10